exosomes analysis
OtherPerform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
NCT Number: NCT03503461
Hypertension is common disorder after renal transplantation and is associated with mortality. Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of hypertension, included in a "Gordon like" syndrome. However, prevalence of NCC activation by CNI is unknown. Our objective is to determine the prevalence of NCC activation three months after transplantation in patient treated by CNI.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hopital Pellegrin - Service Néphrologie, transplantation, dialyse et aphérèse, Bordeaux, France
Hypertension is common disorder after renal transplantation and is associated with mortality. Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of hypertension, included in a "Gordon like" syndrome. Gordon syndrome is a rare genetic disorder where NCC cotransporter is overactivated and cause hypertension, metabolic acidosis and tendency to hyperkaliemia. Few studies evaluated NCC expression by exosomes techniques in human kidney transplant, and mostly compared NCC expression in specific subpopulation (for example with or without hypertension). Thus, prevalence of NCC activation by CNI is unknown. To determine it, we will include prospective patients in Bordeaux and la Réunion who undergo urine and blood tests three months after transplantation, and a control group with no transplantation and no use of CNI. First, we will compare kidney recipients and control and use immunoblot to quantify NCC expression in urinary exosomes to identify the population of transplanted with a high activation. Then, we will analyze the relationship between NCC activation and clinicobiological features of Gordon's syndrome.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
For kidney transplant group :
For control group :
Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
Time frame: Inclusion day
Dosage of NCC cotransporter expression in urinary exosomes samples in both groups.
Time frame: Inclusion day
Dosage of phosphorylated NCC cotransporter expression in urinary exosomes samples in both groups.
Time frame: Inclusion day
Dosage of pendrine expression in urinary exosomes samples in kidney transplant group.
University Hospital, Bordeaux
Other
Evaluation of the Prevalence of an Hyperactivation of NCC Cotransporter Three Months After Kidney Transplantation in Recipients Treated by Calcineurin Inhibitors
Acronym: MANGUE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03102996
Acid-Base Imbalance, Acidosis
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT02827695
Behavior, Cardiovascular Diseases
Charleston, South Carolina, United States
View Trial DetailsNCT02644395
Cardiovascular Diseases, Hypertension
Rotterdam, Netherlands
View Trial DetailsNCT05934383
Cardiovascular Diseases, Hypertension
Rotterdam, Netherlands
View Trial Details